Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound?

AI-generated analysis

📈 Charles River Laboratories International (CRL) stock has rebounded 8.8% over the last 7 days and 28.5% year-to-date despite a broader long-term decline of 43.4% over five years.

💰 A Discounted Cash Flow (DCF) model suggests CRL is currently overvalued by approximately 29.4%, with an estimated intrinsic value of $140.41 versus the current price of around $181.68.

📊 Based on a Price-to-Sales (P/S) ratio analysis, CRL trades at 2.23x, which is below both its peer group average of 3.43x and industry average of 3.50x.

🎯 Simply Wall St's proprietary "Fair Ratio" framework values the stock at 2.87x P/S, indicating it may be trading below its specific fair valuation when adjusted for growth and risk.

🧠 The article introduces "Narratives" as a method to compare investor expectations by modeling future revenue, earnings, margins, and fair value scenarios ranging from $135.89 to $261.63.

🐂 A bullish case narrative projects a fair value of roughly $313.61, implying the stock is undervalued by about 42.1% at current levels if high growth assumptions are met.

🧬 The bull case specifically highlights potential strategic advantages from acquiring K.F. in Cambodia to secure long-term access to non-human primates for preclinical research.

⚖️ DCF analysis relies on a two-stage free cash flow model projecting $368.5 million in the latest year and extending forecasts up to $444.99 million by 2035.

📉 The valuation gap between the current market price and intrinsic value suggests CRL may face short-term headwinds despite recent positive momentum.

🏭 Investors are encouraged to evaluate whether the stock's narrative aligns with their own expectations regarding future revenue growth and profit margins before deciding on a position.

Bullish Signals
  • Charles River Laboratories delivered strong recent performance with an 8.8% return over the last 7 days and 28.5% year-to-date.
  • The company projects Free Cash Flow growth to $379.7 million in 2026 and $402.7 million in 2027, demonstrating upward trajectory.
  • A leading community narrative identifies the stock as roughly 42.1% undervalued compared to a fair value of about US$313.61 per share.
  • The Bull Case assumes robust revenue growth of 9.0%, which is significantly higher than the current market expectations.
  • Charles River Laboratories is pursuing a strategic acquisition of K.F. in Cambodia to secure long-term access to non-human primates, a constrained resource critical for preclinical research.
Risk Factors
  • The stock is trading at US$181.68, while the Discounted Cash Flow model estimates an intrinsic value of only US$140.41, suggesting the shares are overvalued by 29.4%.
  • Historical performance has been poor, with a 5-year return decline of 43.4% and a 3-year decline of 7.2%, despite recent short-term gains.
  • The current Price-to-Sales ratio of 2.23x is significantly below both the Life Sciences industry average of 3.50x and the peer group average of 3.43x, indicating weaker relative valuation support.
  • Community narratives provide a range of fair values starting as low as US$135.89, implying substantial downside risk if lower growth assumptions materialize.
  • Future revenue growth assumptions vary widely among different valuations, with some scenarios projecting only 3.1% annual growth by 2029.
  • Analysts project Free Cash Flow growth from $368.5 million in the last twelve months to $402.7 million in 2026, a modest expansion that may not fully justify current pricing.
Full Analysis
This article from Simply Wall St analyzes the valuation of Charles River Laboratories International (CRL) following a recent price rebound, questioning whether the current share price of approximately US$181.68 represents fair value or a mispricing opportunity. The stock has risen 8.8% over the last week but remains down 10.2% year-to-date and 43.4% over the past five years, while gaining 28.5% in the last 12 months alone. The analysis begins with a Discounted Cash Flow (DCF) model using a two-stage free cash flow to equity approach, which projects intrinsic value at US$140.41 per share based on free cash flow estimates extending to 2035. Under this scenario, the current market price suggests the stock is overvalued by roughly 29.4%. The report then shifts to Price-to-Sales (P/S) metrics, noting that CRL currently trades at a P/S ratio of 2.23x, which is below the Life Sciences industry average of 3.50x and the peer group average of 3.43x. The article introduces Simply Wall St's proprietary "Fair Ratio" model, which calculates a fair P/S of 2.87x after adjusting for growth, margins, and risk. Since the stock is trading below this proprietary fair ratio, it suggests CRL may actually be undervalued when compared to its specific operational profile rather than raw industry averages. Finally, the article introduces the concept of "Narratives" to provide a broader context for valuation beyond single-point estimates, presenting three different community-driven outlooks with fair values ranging from US$135.89 to US$261.63 based on varying assumptions about revenue growth and profit margins. The piece concludes by previewing the company's "Bull Case" narrative, which sets a fair value of around US$313.61, implying the stock is undervalued by approximately 42% at current prices. This bullish view specifically highlights the strategic importance of CRL acquiring K.F. in Cambodia to secure long-term access to non-human primates, a resource currently considered constrained for preclinical research purposes.